Welcome to our dedicated page for Tenon Medical SEC filings (Ticker: TNON), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Tenon Medical, Inc. filings document its medical-device business, public securities, and material events tied to sacroiliac joint treatment products. Current Reports on Form 8-K cover financial results, unaudited revenue releases, FDA-cleared product updates, and corporate communications related to the Catamaran System and SImmetry® portfolio.
The filing record also discloses securities purchase agreements, senior convertible notes, private placements of common stock and warrants, restricted stock unit grants under the 2022 Equity Incentive Plan, annual meeting voting matters, Nasdaq listing-compliance notices, and amended acquisition disclosures with financial statements and pro forma information for the SiVantage asset acquisition.
Tenon Medical, Inc. (TNON) filed an amended current report to correct details of a recently issued convertible note financing. The amendment clarifies that the company issued an aggregate principal amount of $5.16 million of 20% Original Issue Discount Senior Convertible Promissory Notes in a private placement, generating approximately $4.3 million in gross proceeds. The notes mature on September 11, 2026, with an option for the company to extend to December 11, 2026, and are convertible after six months at a price equal to 80% of the three-day VWAP, with a corrected floor price of $0.1567. If the maturity is extended, principal increases by 5%; any prepayment is at 102.5% of principal, and 15% of net proceeds from future securities financings must be used to prepay the notes. Tenon agreed to pay its placement agent a 7% cash fee plus $65,000 in expenses. The offering relied on Section 4(a)(2) and Regulation D/Rule 506(b) exemptions from registration.
Tenon Medical, Inc. (TNON) reports that on August 24, 2026 it received written notice from Nasdaq’s Listing Qualifications staff that it has regained compliance with the minimum bid price requirement under Nasdaq Listing Rule 5550(a)(2). Nasdaq has confirmed that this compliance matter is now closed, meaning the company’s common stock and warrants continue to be listed on The Nasdaq Stock Market LLC.
Tenon Medical, Inc. is establishing a shelf registration that permits issuance, from time to time, of up to $100,000,000 of common stock, preferred stock, warrants, debt securities, rights, or units. Specific terms and pricing for each issuance will be set in separate prospectus supplements.
Within this shelf, Tenon has entered into an at-the-market (ATM) sales agreement with A.G.P./Alliance Global Partners to sell up to $4,397,821 of common stock on Nasdaq or other permitted markets. These primary offerings are limited by General Instruction I.B.6 to no more than one‑third of Tenon’s $13,193,463 public float in any 12‑month period while the float remains below $75 million.
Net proceeds are intended for expanding the commercial footprint of Tenon’s sacroiliac joint fusion portfolio (including clinician training and sales force expansion), clinical research to support reimbursement, research and development and new launches, added inventory and instrumentation, marketing, working capital, and other general corporate purposes. Tenon highlights its status as an emerging growth company and smaller reporting company and its auditor has included a going concern explanatory paragraph regarding the company’s ability to continue operations.
Armistice Capital, LLC and Steven Boyd report a significant ownership position in Tenon Medical, Inc. common stock. They report beneficial ownership of 54,554 shares of common stock, representing 9.99% of the outstanding class. All reported shares are held through Armistice Capital Master Fund Ltd., for which Armistice Capital serves as investment manager.
The reporting persons state they have shared voting and dispositive power over all 54,554 shares and no sole voting or dispositive power. Armistice Capital and Mr. Boyd may be deemed to beneficially own the securities held by the Master Fund by virtue of an Investment Management Agreement, while the Master Fund is identified as having the right to receive dividends and sale proceeds from these securities.
Tenon Medical, Inc. reported higher revenue but continuing losses for the quarter ended June 30, 2026. Quarterly revenue was $1.3 million, up from $0.6 million a year earlier, with gross margin improving to 64% from 43% as procedure volumes grew and the SImmetry+ system contributed.
The company still operates at a loss, with a net loss of $4.1 million for the quarter and $7.5 million for the first half of 2026. Cash and cash equivalents fell to $1.7 million, while total liabilities increased to $11.7 million, resulting in a stockholders’ deficit of $1.7 million. Management states there is substantial doubt about the ability to continue as a going concern, even after receiving $3.6 million of net proceeds from a July 2026 equity offering.
Tenon issued 20% original issue discount senior convertible promissory notes in March 2026, creating a $475 thousand derivative liability. The company also effected a 1-for-35 reverse stock split in August 2026 to address Nasdaq minimum bid-price requirements and previously regained compliance with Nasdaq’s stockholders’ equity rule following the July offering. Disclosure controls and procedures are deemed not effective due to a material weakness from limited segregation of duties.
Tenon Medical, Inc. reported strong top-line growth but continued losses for the quarter ended June 30, 2026. Revenue was $1.3 million, up 127% from the prior-year quarter, driven by a higher number of surgical procedures and added revenue from the SImmetry®+ System. Gross profit rose to $0.8 million with a 64% gross margin, compared with 43% a year earlier, reflecting higher volume and better absorption of fixed production costs.
Operating expenses increased to $4.2 million, mainly from higher sales and marketing spending for commercial expansion and SImmetry®+ rollout, and greater research and development investment. Net loss widened to $4.1 million (basic and diluted loss of $12.35 per share). Cash and cash equivalents were $1.7 million at June 30, 2026, versus $3.8 million at year-end, while current liabilities rose sharply and stockholders’ equity moved to a $1.7 million deficit.
Subsequent to quarter end, Tenon closed a public offering with $4.2 million in gross proceeds and approximately $3.6 million in net proceeds, intended in part to repay outstanding $5.2 million convertible notes maturing September 11, 2026 (extendable to December 11, 2026). The company also received FDA 510(k) clearance for an updated Catamaran® SI Joint Fusion System and highlighted record monthly case volume in July 2026. Forward-looking language cites risks including its ability to continue as a going concern, raise additional capital, and maintain Nasdaq listing compliance.
Tenon Medical, Inc. filed a Form S-3 shelf registration that permits the company to offer and sell, from time to time, up to $100,000,000 of common stock, preferred stock, warrants, debt securities, rights, or units. The filing also includes an at-the-market program to sell up to $4,397,821 of common stock through A.G.P./Alliance Global Partners. Pursuant to General Instruction I.B.6, primary offerings are limited to one-third of Tenon’s public float. As of August 10, 2026, public float was $13,193,463, based on 606,596 non-affiliate shares. Auditors’ reports on 2025 and 2024 financial statements include an explanatory paragraph about substantial doubt regarding Tenon’s ability to continue as a going concern.
Tenon Medical, Inc. approved and implemented a 1-for-35 reverse stock split of its common stock. A Certificate of Amendment was filed in Delaware on August 6, 2026, and the split became effective at 12:01 a.m. Eastern Time on August 10, 2026.
Every 35 shares of issued and outstanding common stock were automatically combined into one share, with fractional shares rounded up to the next whole share. The common stock continues to trade on the Nasdaq Capital Market under the symbol "TNON", with a new CUSIP number 88066N402.
Proportionate adjustments were made to stock options, warrants, equity plan reserves and restricted stock units. The company stated that the primary goal of the reverse split is to increase the per share market price of its common stock to meet the $1.00 average closing price requirement for continued listing on the Nasdaq Capital Market.
Tenon Medical, Inc. director Robert K. Weigle converted 10,732 Restricted Stock Units, granted on October 13, 2025, into 10,732 shares of common stock on July 31, 2026 at $0.00 per share. After this RSU conversion, he directly held 18,284 shares of Tenon Medical common stock.